Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690975 · ClinicalTrials.gov registry record · Phase 1
Benzonatate Dose Tolerance Study
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01690975: Completed Phase 1 study, sponsored by Pfizer.
NCT01690975 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01690975, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single-center, randomized, third party blind, placebo controlled, dose escalation study of benzonatate following single dose administration. The primary oobjective is to assess the safety and tolerability of increasing oral doses of benzonatate following single dose administration in healthy male and female subjects.
Interventions
- DRUG Placebo
- DRUG Benzonatate - 400 mg
- DRUG Benzonatate - 600 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
What the finished NCT01690975 record still lists
NCT01690975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01690975 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01690975 about?
NCT01690975 is a clinical study titled "Benzonatate Dose Tolerance Study". This is a single-center, randomized, third party blind, placebo controlled, dose escalation study of benzonatate following single dose administration. The primary oobjective is to assess the safety and tolerability of increasing oral doses of benzonatate following single dose administration in healt...
What is the current status of trial NCT01690975?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01690975?
The interventions under investigation include: Placebo (DRUG), Benzonatate - 400 mg (DRUG), Benzonatate - 600 mg (DRUG).
Who is sponsoring clinical trial NCT01690975?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01690975's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia